Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 142Leukemia 41Leukemia, Myeloid, Chronic-Phase 35Blast Crisis 17Philadelphia Chromosome 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Leukemia, Myeloid, Accelerated Phase 10Leukemia, Myeloid 9Primary Myelofibrosis 7Leukemia, Myelomonocytic, Chronic 7Leukemia, Myeloid, Acute 7Polycythemia Vera 6Myeloproliferative Disorders 6Hypereosinophilic Syndrome 5Hematologic Neoplasms 5Hematologic Diseases 5Bone Marrow Diseases 5Multiple Myeloma 4Gastrointestinal Stromal Tumors 4Thrombocythemia, Essential 3Myelodysplastic Syndromes 3Mastocytosis 3Leukemia, Lymphocytic, Chronic, B-Cell 3Bronchiolitis Obliterans Syndrome 3Recurrence 2Pdgfra-Associated Chronic Eosinophilic Leukemia 2Neoplasms by Histologic Type 2Neoplasms 2Neoplasm, Residual 2Mastocytosis, Systemic 2

Interventions

ponatinib 4fludarabine phosphate 2fludarabine 2Whole-Body Irradiation 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Melphalan 2Imatinib Mesylate 2Cyclophosphamide 2Busulfan 2Bone Marrow Transplantation 2trametinib 1ruxolitinib 1nilotinib 1dabrafenib 1cobimetinib 1bosutinib 1Vemurafenib 1CPI-0610 1BID protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms by Histologic Type × Imatinib Mesylate × Myeloid × Clear all
NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pfizer

Phase 3 Completed
536 enrolled 24 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01650805 2014-11-17

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Ariad Pharmaceuticals

Phase 3 Terminated
307 enrolled 11 charts
LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡